Revefenacin: Difference between revisions
Jump to navigation
Jump to search
Line 35: | Line 35: | ||
==Clinical Studies== | ==Clinical Studies== | ||
Trials: | |||
*Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD | |||
*88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better) | |||
==How is it supplied== | ==How is it supplied== |
Revision as of 03:44, 8 October 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]
Overview
Adult Indications and Dosage
- The agreed dosage is 175 micrograms per day
- Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
- Makes it easy for patients with pulmonary problems
Pediatric Indications and Dosage
Contradictions
Warnings
Adverse Reactions
Side Effects
- Headache
- Cough
- Problems regarding the upper respiratory system
- Back Pain
Drug Interactions
Use in Specific Populations
IV Compatibility
- Intravenous solution in healthy volunteers
- Volume of distribution was 218 L
- Intravenous solution radioactivity:
- 54% came out as solid waste
- 27% came out as liquid waste
Pharmacology
Clinical Studies
Trials:
- Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
- 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)
How is it supplied
Patient Counseling Information
Precautions with Alcohol
Brand Names
- Yupelri